Naoki Taka

Discovery of Tofogliflozin, a Novel <i>C</i>-Arylglucoside with an <i>O</i>-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi et al. · Journal of Medicinal Chemistry · 2012 · 168 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi et al. · Molecular Cancer Therapeutics · 2014 · 120 citations · Full text

Medicine, Oncology, Pharmacology +15

Discovery of [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Hirosato Ebiike, Naoki Taka, Masayuki Matsushita et al. · Journal of Medicinal Chemistry · 2016 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

6-Substituted 2,2-Bis(fluoromethyl)-benzopyran-4-carboxamide K+ channel openers

Naoki Taka, Hiroshi Koga, Haruhiko Sato et al. · Bioorganic & Medicinal Chemistry · 2000 · 24 citations

Natural Sciences, Chemistry, Pharmacology +4

5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Yoshihito Ohtake, Tsutomu Sato, Hiroharu Matsuoka et al. · Bioorganic & Medicinal Chemistry · 2011 · 23 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16